REG - Kromek Group PLC - Kromek Secures $0.8m Order for D3S ID

KromekAnnouncement

09/01/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230109:nRSI0147Ma&default-theme=true

RNS Number : 0147M  Kromek Group PLC  09 January 2023

9 January 2023

Kromek Group plc

("Kromek" or the "Group")

 

Kromek Secures $0.8m Order for D3S ID

Repeat order from US government customer for wearable nuclear radiation
detector

Kromek Group plc (AIM: KMK), a leading developer of radiation and
bio-detection technology solutions for the advanced imaging and CBRN detection
segments, is pleased to announce that it has secured a repeat order, worth
$0.8m, from a US government customer for its D3S ID wearable nuclear radiation
detector. Delivery and revenue recognition is expected to occur in the Group's
current financial year.

 

D3S ID gamma neutron detector

The D3S ID gamma neutron detector is a wearable Radiation Isotope Identifier
("RIID") designed for first responders, armed forces, border security and
other CBRN experts. Unlike a conventional RIID, it is a pocket-sized device
and is small and light enough to be wearable and concealable. It can recognise
isotopes and neutrons in seconds and is designed to detect radiological
threats like dirty bombs, radioactive contamination, smuggling of radioactive
substances and radiation at the scene of an accident or terrorist attack.

 

Arnab Basu, CEO of Kromek Group, said: "This repeat order affirms the
importance of our nuclear radiation detection technology and the strength of
our relationship with our US governmental customers. We are continuing to see
heightened interest in our CBRN solutions, particularly from governments, and
expect this momentum to be sustained given the ongoing challenges in the
geopolitical environment."

 

ENDS

 

For further information, please contact:

 

 Kromek Group plc
 Arnab Basu, CEO                                                   +44 (0)1740 626 060

 Paul Farquhar, CFO

 finnCap Ltd (Nominated Adviser and Broker)                         
 Geoff Nash/Seamus Fricker/George Dollemore - Corporate Finance    +44 (0)20 7220 0500

 Tim Redfern/Charlotte Sutcliffe - ECM

 Gracechurch Group (Financial PR)
 Harry Chathli/Claire Norbury                                      +44 (0)20 4582 3500

Kromek Group plc

 

Kromek Group plc is a leading developer of radiation detection and
bio-detection technology solutions for the advanced imaging and CBRN detection
segments. Headquartered in County Durham, UK, Kromek has manufacturing
operations in the UK and US, delivering on the vision of enhancing the quality
of life through innovative detection technology solutions.

 

The advanced imaging segment comprises the medical (including CT and SPECT),
security and industrial markets. Kromek provides its OEM customers with
detector components, based on its core cadmium zinc telluride (CZT) platform,
to enable better detection of diseases such as cancer and Alzheimer's,
contamination in industrial manufacture and explosives in aviation
settings.

 

In CBRN detection, the Group provides nuclear radiation detection solutions to
the global homeland defence and security market. Kromek's compact, handheld,
high-performance radiation detectors, based on advanced scintillation
technology, are primarily used to protect critical infrastructure and urban
environments from the threat of 'dirty bombs'.

 

The Group is also developing bio-security solutions in the CBRN detection
segment. These consist of fully automated and autonomous systems to detect a
wide range of airborne pathogens.

 

Kromek is listed on AIM, a market of the London Stock Exchange, under the
trading symbol 'KMK'.

 

Further information is available at www.kromek.com (http://www.kromek.com/)
.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCSSUFUAEDSESF